USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BUFFALO BIOLABS, LLC
Address:
73 HIGH ST
BUFFALO, NY 14203-1149
EIN:
126472149
DUNS:
830459546
Number of Employees:
31
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $663,716.00 4
SBIR Phase II $1,496,764.00 1
STTR Phase I $504,608.00 3

Award List:

Targeting MLL As Anticancer Therapy for Infant Acute Lymphoblastic Leukemia

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$130,694.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Advances in treatment strategies have increased the long-term survival of children with acute lymphoblastic leukemia (ALL). However, the outlook of infants with ALL remains dismal with long-term survival rates of only 3 0-50%. Therefore, new treatments are… More

Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$104,608.00
Agency:
HHS
Principal Investigator:
Research Institution:
ROSWELL PARK CANCER INSTITUTE CORP
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): One of the major problems in the fight against cancer is the intrinsic or acquired resistance of tumors to current cancer treatments, particularly that associated with multidrug transporters (MDT; e.g. P-glycoprotein (P -gp) and the multidrug associated protein… More

Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$109,719.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Systemic treatment with the bacterial flagellin protein, a Toll-like receptor 5 (TLR5) agonist, provides protection against high dose radiation through activation of nuclear factor-(B (NF-(B). NF-(B signaling induces mu ltiple factors that contribute to cell… More

TAS::75 0849::TAS SBIR TOPIC 255 PHASE II DEVELOPMENT OF ANTICANCER AGENTS

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,496,764.00
Agency:
HHS
Principal Investigator:
Catherine Burkhart – 716-845-1065
Abstract:
Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat shock response) are prominent features in many cancer types. Such alterations have been associated with poor response of tumors to conventional antitumor treatments. This is true for such cancers as non-small cell… More

Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Asoke K. Mal – 716-845-4133
Research Institution:
ROSWELL PARK CANCER INSTITUTE CORP
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It accounts for 3.5% of all malignancies in children. Despite multimodality therapeutic treatment approaches,… More

Testing of novel anti-cancer compounds Curaxins against pancreatic cancer

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Katerina Gurova – 716-849-6810
Research Institution:
ROSWELL PARK CANCER INSTITUTE CORP
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches. This proposal is focused on determining the therapeutic potential of a new class of candidateanti-cancer agents named Curaxins (CXs) for… More

IGF::OT::IGF OTHER FUNCTIONS RandD - MEDICAL BIOMEDICAL (BASIC RESEARCH)

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
Anatoli Gleiberman – 716-845-1065
Abstract:
Head and neck (HandN) cancer is recognized as a significant threat to public health and a substantial economic challenge. The efficacy of radiotherapy widely used to treat HandN cancer is limited by severe adverse effects, such as mucositis. Currently, there are no drugs effectively preventing these… More

Deimmunized TLR5 Agonist for Anticancer Therapy

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$223,303.00
Agency:
HHS
Principal Investigator:
Vadim Mett – 716-849-6810
Abstract:
ABSTRACT: Radiotherapy is widely used to treat various types of cancer; however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tissues in the tumor environment. Due to the scale of thisproblem and the current lack of safe and… More